Clozapine is the Antipsychotic Most Strongly Associated with Agranulocytosis
Clozapine is definitively the antipsychotic that causes agranulocytosis, with a cumulative incidence of approximately 0.8-1.4% compared to 0.13% for all other antipsychotics combined 1, 2.
Risk Profile and Comparative Data
Clozapine carries by far the highest risk among all antipsychotics for inducing agranulocytosis. The evidence demonstrates:
- Clozapine: 1.57 cases per 1,000 exposed patients 2
- Perazine (second highest): 0.52 per 1,000 exposed patients 2
- Quetiapine: 0.23 per 1,000 exposed patients 2
- Olanzapine: 0.13 per 1,000 exposed patients 2
- All non-clozapine antipsychotics combined: 0.13% cumulative incidence 1
This means clozapine has approximately 10-fold higher risk than all other antipsychotics, making it the unequivocal answer to this question.
Temporal Risk Pattern
The risk is not uniform throughout treatment. The highest risk occurs in the first 18 weeks of treatment, with 61 of 73 cases (84%) occurring within the first 3 months 3. The risk then decreases steeply over time, from an adjusted odds ratio of 36.01 for less than 6 months of use to 4.38 for 54+ months of use 1.
Clinical Monitoring Implications
Recent consensus guidelines 4 now recommend:
- Weekly ANC monitoring for the first 18 weeks
- Monthly monitoring from weeks 18 through 2 years
- Discontinuation of routine ANC monitoring after 2 years of stable treatment
The ANC threshold for considering clozapine cessation has been lowered to 1.0×10⁹ cells per L (or 0.5×10⁹ cells per L for DARC/ACKR1-null individuals) 4, reflecting updated understanding that previous thresholds led to unnecessary treatment interruptions.
Important Caveats
While clozapine's agranulocytosis risk is real and requires monitoring, the actual mortality from clozapine-induced agranulocytosis is extremely low (only 1 death among 3,559 patients starting clozapine in the Finnish cohort) 1. The systematic review found only 0.47% incidence when clozapine was continued despite mild neutropenia 5, suggesting the risk may be lower than historically perceived when appropriate monitoring is maintained.
Risk factors include: female sex for neutropenia specifically, and increasing age for agranulocytosis 3.